Search

Your search keyword '"Lorenzo Chiatti"' showing total 2 results
Start Over Author "Lorenzo Chiatti" Topic covid-19
2 results on '"Lorenzo Chiatti"'

1. Vaccine-induced massive pulmonary embolism and thrombocytopenia following a single dose of Janssen Ad26.COV2.S vaccination

Author

Rosa Curcio, Vito Gandolfo, Riccardo Alcidi, Luciano Giacomino, Tommaso Campanella, Genni Casarola, Rachele Rossi, Lorenzo Chiatti, Marco D'Abbondanza, Rita Commissari, Paolo Gresele, Giacomo Pucci, and Gaetano Vaudo

Subjects
COVID-19, Janssen, AD26.COV2.S, Vaccination, Vaccine-induced thrombosis with thrombocytopenia, Pulmonary embolism, Infectious and parasitic diseases, RC109-216
Abstract

ABSTRACT: Vaccine-induced immune thrombotic thrombocytopenia (VITT) has emerged as a rare side effect of adenoviral vector-based vaccines against coronavirus disease 2019 (COVID-19), and is most frequently reported after use of the Vaxzevria (AstraZeneca) vaccine. This report describes a case of severe thrombocytopenia associated with massive pulmonary embolism and portal vein thrombosis occurring 13 days after the administration of the single-dose adenoviral vector-based vaccine Ad26.COV2.S (Janssen Vaccines). Based on early clinical suspicion, the patient quickly received treatment with corticosteroids and intravenous immunoglobulin, followed by a rapid increase in platelet count that allowed timely administration of full-dose anticoagulation. Treatment with intravenous immunoglobulin, however, could mask the ability of anti-platelet factor 4-heparin antibodies to bind and activate platelets in the presence of heparin, leading to false-negative results on the immunoassay functional test. Therefore, if VITT is suspected, blood samples for diagnostic confirmation should be collected prior to any treatment to improve diagnostic performance.

Published
2022
Full Text
View/download PDF

2. Handgrip strength is associated with adverse outcomes in patients hospitalized for COVID-19-associated pneumonia

Author

Giacomo Pucci, Marco D’Abbondanza, Rosa Curcio, Riccardo Alcidi, Tommaso Campanella, Lorenzo Chiatti, Vito Gandolfo, Vito Veca, Genni Casarola, Maria Comasia Leone, Rachele Rossi, Alessio Alberti, Leandro Sanesi, Massimiliano Cavallo, and Gaetano Vaudo

Subjects
Hospitalization, Male, Oxygen, Hand Strength, Cardiovascular Diseases, Emergency Medicine, Internal Medicine, COVID-19, Humans, Female, Body Mass Index
Abstract

Handgrip strength (HGS), a simple tool for the evaluation of muscular strength, is independently associated with negative prognosis in many diseases. It is unknown whether HGS is prognostically relevant in COVID-19. We evaluated the ability of HGS to predict clinical outcomes in people with COVID-19-related pneumonia. 118 patients (66% men, 63 ± 12 years), consecutively hospitalized to the “Santa Maria” Terni University Hospital for COVID-19-related pneumonia and respiratory failure, underwent HGS measurement (Jamar hand-dynamometer) at ward admission. HGS was normalized to weight2/3 (nHGS) The main end-point was the first occurrence of death and/or endotracheal intubation at 14 days. Twenty-two patients reached the main end-point. In the Kaplan–Meyer analysis, the Log rank test showed significant differences between subjects with lower than mean HGS normalized to weight2/3 (nHGS) (2/3) vs subjects with higher than mean nHGS. (p = 0.03). In a Cox-proportional hazard model, nHGS inversely predicted the main end-point (hazard ratio, HR = 1.99 each 0.5 kg/Kg2/3 decrease, p = 0.03), independently from age, sex, body mass index, ratio of partial pressure arterial oxygen and fraction of inspired oxygen (PaO2/FiO2 ratio), hypertension, diabetes, estimated glomerular filtration rate and history of previous cardiovascular cardiovascular disease. These two latter also showed independent association with the main end-point (HR 1.30, p = 0.03 and 3.89, p

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results